



Assessing the efficiency of constructed wetlands in removing PPCPs from treated wastewater and mitigating the ecotoxicological impacts

Mohamed Bayati^{a,b,c}, Thi L. Ho^{a,d}, Danh C. Vu^e, Fengzhen Wang^f, Elizabeth Rogers^{a,h}, Craig Cuvellier^g, Steve Huebotter^g, Enos C. Inniss^b, Ranjith Udawatta^a, Shibu Jose^{a,h}, Chung-Ho Lin^{a,h,*}

^a Center for Agroforestry, University of Missouri-Columbia, USA

^b Department of Civil and Environmental Engineering, University of Missouri-Columbia, USA

^c Department of Environmental Engineering, Tikrit University, Iraq

^d Center of Core Facilities, Cuu Long Delta Rice Research Institute, Viet Nam

^e Faculty of Technology, Van Lang University, Ho Chi Minh City, Viet Nam

^f School of Art and design, Wuhan University of Technology, China

^g Columbia Regional Wastewater Treatment Plant, Missouri, USA

^h School of Natural Resources, University of Missouri-Columbia, USA

ARTICLE INFO

Keywords:

Wetlands
PPCPs
Missouri river
Aquatic risk assessment
ToxPi
ECOTOX

ABSTRACT

The prevalence of pharmaceuticals and personal care products (PPCPs) in municipal wastewater has led to increased concerns about their impact on both human health and ecosystem. The constructed wetlands have been recognized as one of the cost-effective and green mitigation approaches to remove the PPCPs in the municipal wastewater. In this study, the effectiveness of a full scale constructed wetlands treatment system (CCWTs) in removing the 36 PPCPs was investigated. The load mass of PPCPs discharged by the wastewater treatment plant into the CCWTs was calculated. Removal efficiencies of PPCPs were evaluated based on physico-chemical properties such as octanol-water partition coefficient (Log k_{ow}), molecular weight (MW, g mol^{-1}) and the acid dissociation constant (pK_a). The CCWTs are especially efficient in removing azithromycin, sertraline, tolfenamic acid, and diphenhydramine with removing efficiency >88%. However, the removal efficiencies of PPCPs in CCWTs exhibit a large variability, depending on physical and chemical properties of the molecules, with 4.7–96.7% for antibiotics, 5–86% for antidepressant and antiseizure drugs, 3.5–88% for NSAIDs, 29–77% for β -blockers and statins and 5.5–94% for other types of PPCPs. In addition, the environmental risk assessment showed that majority of the PPCPs (excluding sulfamethoxazole) in the effluent yielded low aquatic risk (risk quotient, $RQ \leq 0.1$) due to the efficiency of CCWTs. The toxicity index scores were calculated by integration of the predicted and available toxicological hazard data into the prioritization ranking algorithm through Toxicological Prioritization Index (ToxPi).

1. Introduction

The prevalence of pharmaceuticals and personal care products (PPCPs) in aquatic environments is the result of direct human disposal and other personal care uses. This has led to increased concerns about their impact on both human health and ecosystem (Larsen et al., 2019; Oulton et al., 2010). Because of the persistence and inherent ability to induce physiological effects in humans at low doses, PPCPs have been classified as emerging pollutants, and have raised increasing concern

over the last decade (Zhang et al., 2014). The PPCPs often contain a large group of chemicals with different physico-chemical properties and structures (Ebele et al., 2017). These include pharmaceutical products (e.g., painkillers, antibiotics, anti-allergic drugs, anti-inflammatory drugs, hormones, and β -blockers) which are used to treat diseases in both humans and animals, along with personal care products (e.g., sunscreens, makeup, deodorant, insect repellants, hand soap, and moisturizers) which are used primarily to enhance the quality of life (Abdallah et al., 2019).

* Corresponding author. School of Natural Resources, University of Missouri-Columbia, USA.
E-mail address: linchu@missouri.edu (C.-H. Lin).

<https://doi.org/10.1016/j.ijheh.2020.113664>

Received 25 July 2020; Received in revised form 8 November 2020; Accepted 9 November 2020

Available online 16 November 2020

1438-4639/© 2020 Elsevier GmbH. All rights reserved.